Name: 글로벌 시장 동향
SKU: PH7851
Availability: InStock

보고서 요약(국문)

개요
전 세계 헬리코박터 파일로리 감염 치료제 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 기록하며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
헬리코박터 파일로리(H. pylori)는 위 또는 십이지장에 감염을 일으킬 수 있는 세균입니다. 이는 소화성 궤양의 가장 흔한 원인균입니다. 또한 헬리코박터 파일로리는 위 점막에 염증과 자극을 유발하여 위염을 일으킬 수 있습니다. 치료하지 않고 장기간 헬리코박터 파일로리 감염을 방치하면 위암으로 이어질 수 있습니다. 헬리코박터 파일로리는 사람 간 전염이 가능하며, 타액, 치태, 대변에서 발견됩니다.
헬리코박터 파일로리 감염은 일반적으로 최소 두 가지 이상의 항생제를 동시에 투여하여 치료합니다. 이는 특정 항생제에 대한 내성 발생을 예방하는 데 도움이 됩니다. 최근 개발된 탈리시아(Talicia)는 두 가지 항생제(리파부틴과 아목시실린)와 양성자 펌프 억제제(오메프라졸)를 하나의 캡슐에 결합한 약물입니다.
시장 동향: 성장 요인
복합 치료제 채택 증가
복합 치료제의 채택이 증가함에 따라 예측 기간 동안 시장 성장이 촉진될 것으로 예상됩니다. 헬리코박터 파일로리는 항생제로 박멸할 수 있지만, 90% 이상의 박멸률을 달성하려면 양성자 펌프 억제제 또는 비스무트와 함께 두 가지 이상의 항생제를 병용해야 합니다.
헬리코박터 파일로리 균주의 항생제 내성 출현은 심각한 문제로 대두되었습니다. 상호 보완적인 작용 기전을 가진 여러 항생제를 병용하면 치료 효과를 높이고 내성 발생 위험을 줄일 수 있습니다.
예를 들어, 아쿰스 제약(Akums Drugs and Pharmaceutical)은 2023년 4월 26일, 아목시실린 + 클라리트로마이신 + 에소메프라졸을 결합한 새로운 복합제인 콤비킷(Combikit)을 출시했습니다. 콤비킷(아목시실린 + 클라리트로마이신 + 에소메프라졸)은 헬리코박터 파일로리(H. pylori) 관련 십이지장 궤양 치료 및 활동성 또는 완치된 소화성 궤양 환자의 H. pylori 박멸을 위해 중앙 의약품 표준 관리 기구(CDSCO)의 승인을 받았습니다.
이 콤비킷은 아목시실린, 클라리트로마이신, 에소메프라졸 세 가지 효과적인 약물의 조합입니다. 이 조합은 H. pylori 박테리아의 성장을 억제하고 위산 생성을 감소시켜 작용합니다. 이 약은 환자가 휴대하기 편리한 포장으로 제공되어 전체 치료 과정을 완료할 수 있습니다.
H. pylori 균주의 항생제 내성 출현은 중요한 문제로 대두되고 있습니다. 상호 보완적인 작용 기전을 가진 여러 항생제를 병용하면 치료 효과를 높이고 내성 발생 위험을 줄일 수 있습니다. 항생제와 프로톤 펌프 억제제(PPI), 그리고 비스무트 함유 화합물을 병용하면 헬리코박터 파일로리(H. pylori) 박멸률을 높이는 것으로 나타났습니다. 이러한 접근법은 흔히 삼중 요법(두 가지 항생제에 PPI 또는 비스무트) 또는 사중 요법(세 가지 항생제에 PPI 또는 비스무트)이라고 불립니다.
예를 들어, 2023년 3월 17일, 엔도(Endo)의 자회사인 파(Par)는 앨러간(Allergan)의 파일레라(Pylera, 비스무트 아구연산칼륨, 메트로니다졸, 테트라사이클린 염산염) 40mg, 125mg, 125mg 캡슐의 첫 번째 제네릭 버전을 출시했습니다. 비스무트 아구연산칼륨, 메트로니다졸, 테트라사이클린 염산염 캡슐은 오메프라졸과 함께 헬리코박터 파일로리 감염 및 십이지장 궤양 질환(현재 또는 지난 5년 이내 병력) 환자의 헬리코박터 파일로리 박멸 치료에 사용됩니다.

또한, 헬리코박터 파일로리 감염의 유병률 증가, 규제 승인 증가, 보다 효과적인 치료법을 위한 임상 시험 증가, 질환 및 치료법에 대한 인식 제고, 그리고 신약 및 치료법 개발의 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.
제약 요인
다양한 치료법과 관련된 부작용, 단기 심혈관 사망 위험 증가와 같은 합병증, 그리고 일부 치료법의 높은 비용은 시장 성장을 저해할 것으로 예상되는 요인입니다.
세분화 분석
전 세계 헬리코박터 파일로리 감염 치료제 시장은 질병 유형, 치료법, 유통 채널 및 지역별로 세분화됩니다.
항생제 부문은 헬리코박터 파일로리 감염 치료제 시장 점유율의 약 59.6%를 차지했습니다.
항생제 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 일반적으로 두 가지 항생제가 처방됩니다. 흔히 사용되는 항생제로는 아목시실린, 클라리트로마이신(비아신), 메트로니idazol(플라질), 테트라사이클린 등이 있습니다. 헬리코박터 파일로리 감염은 일반적으로 최소 두 가지 이상의 항생제를 동시에 사용하여 치료합니다. 이는 박테리아가 특정 항생제에 대한 내성을 키우는 것을 방지하는 데 도움이 됩니다.
헬리코박터 파일로리는 위벽에 서식하는 박테리아의 일종입니다. 항생제는 박테리아 감염에 효과적이므로 헬리코박터 파일로리 치료에 적합한 선택입니다. 헬리코박터 파일로리는 특정 항생제에 내성을 나타내는 것으로 알려져 있습니다. 항생제를 병용 투여하면 항생제 내성 위험을 줄이고 박테리아 박멸 성공률을 높일 수 있습니다. 항생제는 헬리코박터 파일로리 박테리아를 죽이고, 위산 억제제는 위산 분비를 줄여 궤양이 치유되도록 돕습니다. 항생제는 양성자 펌프 억제제와 같은 다른 계열의 약물과 병용할 때도 매우 효과적입니다.

예를 들어, 2020년 3월 15일, 레드힐 바이오파마(RedHill Biopharma)는 성인의 헬리코박터 파일로리(H. pylori) 감염 치료를 위한 서방형 캡슐인 탈리시아(Talicia, 두 가지 항생제(아목시실린과 리파부틴) 및 양성자 펌프 억제제(PPI)(오메프라졸)의 복합제)를 출시했습니다.
지역 분석
북미는 시장 점유율의 약 42.5%를 차지했습니다.
북미 지역은 주요 업체들의 강력한 입지와 헬리코박터 파일로리 감염 증가 추세로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 북미, 특히 미국은 제약 회사와 같은 주요 업체들의 강력한 존재감으로 잘 알려져 있습니다. 이러한 주요 업체들의 활발한 연구 활동은 헬리코박터 파일로리 박멸을 위한 새로운 치료제 출시로 이어집니다.

예를 들어, 2023년 10월 30일, 파톰 파마슈티컬스(Phathom Pharmaceuticals, Inc.)는 성인의 헬리코박터 파일로리(H. pylori) 감염 치료를 위한 보코즈나 트리플 팩(VOQUEZNA TRIPLE PAK, 보노프라잔 정제, 아목시실린 캡슐, 클라리트로마이신 정제)과 보코즈나 듀얼 팩(VOQUEZNA DUAL PAK, 보노프라잔 정제, 아목시실린 캡슐)의 보노프라잔 정제 제형 변경에 대한 미국 식품의약국(FDA)의 사전 승인 보충서(PAS) 승인을 받았습니다. 보코즈나 치료 요법은 보노프라잔과 함께 편리하게 포장된 항생제를 함유하고 있으며, 이는 30년 만에 미국에서 승인된 새로운 약물 계열의 혁신적인 위산 억제제입니다.
더욱이, 북미, 특히 미국에서 헬리코박터 파일로리 감염 유병률이 증가하고 있으며, 생활 방식, 사회경제적 지위, 의료 인프라와 같은 요인이 이러한 감염 발생에 영향을 미칠 수 있습니다. 높은 유병률로 인해 헬리코박터 파일로리 치료제에 대한 수요가 더 높을 것으로 예상됩니다.
예를 들어, 미국 국립보건원(NIH)의 2021년 자료에 따르면 미국인의 약 30~40%가 헬리코박터 파일로리균에 감염됩니다. 대부분 어린 시절에 감염되며, 일반적으로 증상을 유발하지는 않습니다. 그러나 일부 사람의 경우 위 내벽의 보호막을 파괴하여 염증을 일으킬 수 있습니다. 이는 위염이나 소화성 궤양으로 이어질 수 있습니다.
경쟁 환경
헬리코박터 파일로리균 감염 치료제 시장의 주요 글로벌 기업으로는 Phathom Pharmaceuticals, Akums Drugs & Pharmaceuticals Ltd., RedHill Biopharma Ltd., Cumberland Pharmaceuticals Inc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Pernix Therapeutics LLC, Astellas Pharma Inc., Faromed Lifesciences LLP 및 Matrix Pharma 등이 있습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 헬리코박터 파일로리 감염 치료제 시장에 상당한 영향을 미쳤습니다. 헬리코박터 파일로리(H. pylori)는 전 세계 인구의 절반에 영향을 미치고 있습니다. 코로나19 팬데믹 기간 동안 항생제 오남용은 H. pylori 박멸률에 영향을 미칠 수 있습니다. COVID-19 팬데믹이 빠르게 확산되면서, 팬데믹 발생 후 2년도 채 되지 않아 클라리트로마이신과 레보플록사신에 대한 H. pylori의 높은 내성률이 나타났습니다. 또한 팬데믹은 전 세계적으로 이러한 치료제의 공급망을 교란시켰습니다.

시장 세분화
질병 유형별
• 1형 헬리코박터 파일로리균
• 2형 헬리코박터 파일로리균
치료제별
• 항생제
o 아목시실린
o 클래리트로마이신 (비아신)
o 메트로니다졸 (플라질)
o 테트라사이클린
o 기타
• 프로톤 펌프 억제제 (PPI)
o 란소프라졸 (프레바시드)
o 오메프라졸 (프릴로섹)
o 판토프라졸 (프로토닉스)
o 라베프라졸 (아시펙스)
o 에소메프라졸 (넥시움)
o 기타
• 히스타민(H-2) 차단제
• 위 점막 보호제
• 비스무트 서브살리실레이트
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o • 독일
• 영국
• 프랑스
• 스페인
• 이탈리아
• 기타 유럽
• 남미
• 브라질
• 아르헨티나
• 기타 남미
• 아시아 태평양
• 중국
• 인도
• 일본
• 호주
• 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유:

• 질병 유형, 치료제, 유통 채널 및 지역별 글로벌 헬리코박터 파일로리 감염 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 헬리코박터 파일로리 감염 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 플레이어의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 헬리코박터 파일로리 감염 치료제 시장 보고서는 약 61개의 표, 59개의 그림, 187페이지로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global helicobacter pylori infection therapeutics market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
H. pylori (Helicobacter pylori) are bacteria that can cause an infection in the stomach or duodenum. It is the most common cause of peptic ulcer disease. H. pylori can also inflame and irritate the stomach lining (gastritis). Untreated, long-term H. pylori infection can lead to stomach cancer. H. pylori can spread from person to person. H. pylori are found in saliva, plaque on teeth and poop.
H. pylori infections are usually treated with at least two different antibiotics at once. This helps prevent the bacteria from developing a resistance to one particular antibiotic. One newer medication, Talicia, combines two antibiotics (rifabutin and amoxicillin) with a proton pump inhibitor (omeprazole) into a single capsule.
Market Dynamics: Drivers
Increasing adoption of combination therapeutics
The increasing adoption of combination therapeutics is expected to drive the market over the forecast period. Helicobacter pylori can be eradicated with the use of antibiotics, however, more than 1 agent has to be used in combination with either a proton pump inhibitor or bismuth to achieve eradication rates of 90% or greater.
The emergence of antibiotic resistance in H. pylori strains has become a significant concern. Combining different antibiotics with complementary mechanisms of action can improve the effectiveness of treatment and reduce the risk of resistance development.
For instance, on April 26, 2023, Akums Drugs and Pharmaceutical launched its latest formulation, a unique Combikit – (Amoxicillin + Clarithromycin + Esomeprazole). Combikit (Amoxicillin + Clarithromycin + Esomeprazole) is approved by the Central Drugs Standard Control Organisation (CDSCO) for the healing of duodenal ulcers associated with Helicobacter pylori (H. pylori) and eradication of H. pylori in patients with active or healed peptic ulcer.
This Combikit is a combination of three effective drugs - Amoxicillin, Clarithromycin and Esomeprazole. This combination works by inhibiting the growth of H. pylori bacteria and reducing the production of gastric acid. The drug is available in a patient-convenient pack for a complete course of therapy.
The emergence of antibiotic resistance in H. pylori strains has become a significant concern. Combining different antibiotics with complementary mechanisms of action can improve the effectiveness of treatment and reduce the risk of resistance development. Combining antibiotics with proton pump inhibitors (PPIs) and bismuth-containing compounds has been shown to enhance the eradication rates of H. pylori. This approach is often referred to as triple therapy (two antibiotics plus a PPI or bismuth) or quadruple therapy (three antibiotics plus a PPI or bismuth).
For instance, on March 17, 2023, Par, an Endo company, is offering the first generic version of Allergan's Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 40 mg, 125 mg and 125 mg capsules. Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, combined with omeprazole are indicated for treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.
Further, the increasing prevalence of helicobacter pylori infection, rising regulatory approvals, increasing clinical trials for more effective therapeutics, increasing awareness about the condition and therapeutics and increasing advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.
Restraints
Factors such as side effects associated with the various therapeutics, complications such as increased risk of short-term cardiovascular mortality and the high cost associated with some therapeutics are the factors expected to hamper the market.
Segment Analysis
The global helicobacter pylori infection therapeutics market is segmented based on disease type, therapeutics, distribution channel and region.
The antibiotics segment accounted for approximately 59.6% of the helicobacter pylori infection therapeutics market share
The antibiotics segment is expected to hold the largest market share over the forecast period. Usually, two antibiotics are prescribed. Among the common choices are amoxicillin, clarithromycin (Biaxin), metronidazole (Flagyl) and tetracycline. H. pylori infections are usually treated with at least two different antibiotics at once. This helps prevent the bacteria from developing a resistance to one particular antibiotic.
H. pylori is a bacterial species that colonizes the stomach lining. Antibiotics are effective against bacterial infections, making them a logical choice for treating H. pylori. H. pylori has shown the ability to develop resistance to certain antibiotics. Using a combination of antibiotics in therapy helps reduce the risk of antibiotic resistance and increases the chances of successful bacterial eradication. The antibiotics kill the H. pylori bacteria and the acid-suppressing medicine reduces stomach acid, so any ulcers can heal. Antibiotics are also very effective by combining with other classes of drugs such as proton pump inhibitors.
For instance, on March 15, 2020, RedHill Biopharma launched Talicia(a combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole)), a delayed-release capsule for treating Helicobacter pylori (H. pylori) infection in adults.
Geographical Analysis
North America accounted for approximately 42.5% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and the increasing prevalence of H.Pylori. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies. This strong presence of major players actively performing in research activities leads to the launch of novel therapeutics for the eradication of Helicobacter pylori.
For instance, on October 30, 2023, Phathom Pharmaceuticals, Inc. cleared the U.S. Food and Drug Administration (FDA) approval of the Prior Approval Supplement (PAS) for the reformulation of vonoprazan tablets for both VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults. VOQUEZNA treatment regimens contain antibiotics conveniently packaged with vonoprazan and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years.
Furthermore, there is an increasing prevalence of H. pylori infections in North America especially in the United States and factors such as lifestyle, socioeconomic status and healthcare infrastructure can influence the occurrence of these infections. Due to the higher prevalence, there may be a greater demand for H. pylori therapeutics.
For instance, according to the National Institute of Health (NIH), 2021, About 30 to 40% of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer.
Competitive Landscape
The major global players in the helicobacter pylori infection therapeutics market include Phathom Pharmaceuticals, Akums Drugs & Pharmaceuticals Ltd., RedHill Biopharma Ltd., Cumberland Pharmaceuticals Inc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Pernix Therapeutics LLC, Astellas Pharma Inc., Faromed Lifesciences LLP and Matrix Pharma among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global helicobacter pylori infection therapeutics market. Helicobacter pylori (H. pylori) is affecting half of the globe. The misuse of antibiotics during the coronavirus disease 2019 (COVID-19) pandemic time can affect H. pylori eradication rates. As the COVID-19 pandemic has moved forward fast, high resistance rates of H. pylori to both clarithromycin and levofloxacin were developed less than two years from the start of the pandemic. The pandemic also disrupted the supply chain of these therapeutics globally.
Market Segmentation
By Disease Type
• Type I H. Pylori
• Type II H. Pylori
By Therapeutics
• Antibiotics
o Amoxicillin
o Clarithromycin (Biaxin)
o Metronidazole (Flagyl)
o Tetracycline
o Others
• Proton Pump Inhibitors (PPIs)
o Lansoprazole (Prevacid)
o Omeprazole (Prilosec)
o Pantoprazole (Protonix)
o Rabeprazole (Aciphex)
o Esomeprazole (Nexium)
o Others
• Histamine (H-2) Blockers
• Stomach-Lining Protectors
• Bismuth Subsalicylate
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global helicobacter pylori infection therapeutics market segmentation based on disease type, therapeutics, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of helicobacter pylori infection therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global helicobacter pylori infection therapeutics market report would provide approximately 61 tables, 59 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Therapeutics
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption of Combination Therapeutics
4.1.2. Restraints
4.1.2.1. Side Effects Associated with the Various Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. PESTEL Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Type I H. Pylori*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Type II H. Pylori
8. By Therapeutics
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
8.1.2. Market Attractiveness Index, By Therapeutics
8.2. Antibiotics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Amoxicillin
8.2.4. Clarithromycin (Biaxin)
8.2.5. Metronidazole (Flagyl)
8.2.6. Tetracycline
8.2.7. Others
8.3. Proton Pump Inhibitors (PPIs)
8.3.1. Lansoprazole (Prevacid)
8.3.2. Omeprazole (Prilosec)
8.3.3. Pantoprazole (Protonix)
8.3.4. Rabeprazole (Aciphex)
8.3.5. Esomeprazole (Nexium)
8.3.6. Others
8.4. Histamine (H-2) Blockers
8.5. Stomach-Lining Protectors
8.6. Bismuth Subsalicylate
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Phathom Pharmaceuticals*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Akums Drugs & Pharmaceuticals Ltd.
12.3. RedHill Biopharma Ltd.
12.4. Cumberland Pharmaceuticals Inc.
12.5. Eisai Co., Ltd.
12.6. Takeda Pharmaceutical Company Limited
12.7. Pernix Therapeutics LLC
12.8. Astellas Pharma Inc.
12.9. Faromed Lifesciences LLP
12.10. Matrix Pharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Phathom Pharmaceuticals, 4.	Key Developments, Akums Drugs & Pharmaceuticals Ltd., RedHill Biopharma Ltd., Cumberland Pharmaceuticals Inc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Pernix Therapeutics LLC, Astellas Pharma Inc., Faromed Lifesciences LLP, Matrix Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Helicobacter Pylori Infection Therapeutics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 7 Global Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2022-2031 (US$ Million)

Table 9 Global Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Helicobacter Pylori Infection Therapeutics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Helicobacter Pylori Infection Therapeutics Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 14 North America Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2022-2031 (US$ Million)

Table 15 North America Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Helicobacter Pylori Infection Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 18 South America Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2022-2031 (US$ Million)

Table 19 South America Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Helicobacter Pylori Infection Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 Europe Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2022-2031 (US$ Million)

Table 23 Europe Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Helicobacter Pylori Infection Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Value, By Therapeutics, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Phathom Pharmaceuticals: Overview

Table 33 Phathom Pharmaceuticals: Product Portfolio

Table 34 Phathom Pharmaceuticals: Key Developments

Table 35 Akums Drugs & Pharmaceuticals Ltd.: Overview

Table 36 Akums Drugs & Pharmaceuticals Ltd.: Product Portfolio

Table 37 Akums Drugs & Pharmaceuticals Ltd.: Key Developments

Table 38 RedHill Biopharma Ltd.: Overview

Table 39 RedHill Biopharma Ltd.: Product Portfolio

Table 40 RedHill Biopharma Ltd.: Key Developments

Table 41 Cumberland Pharmaceuticals Inc.: Overview

Table 42 Cumberland Pharmaceuticals Inc.: Product Portfolio

Table 43 Cumberland Pharmaceuticals Inc.: Key Developments

Table 44 Eisai Co., Ltd.: Overview

Table 45 Eisai Co., Ltd.: Product Portfolio

Table 46 Eisai Co., Ltd.: Key Developments

Table 47 Takeda Pharmaceutical Company Limited: Overview

Table 48 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 49 Takeda Pharmaceutical Company Limited: Key Developments

Table 50 Pernix Therapeutics LLC: Overview

Table 51 Pernix Therapeutics LLC: Product Portfolio

Table 52 Pernix Therapeutics LLC: Key Developments

Table 53 Astellas Pharma Inc.: Overview

Table 54 Astellas Pharma Inc.: Product Portfolio

Table 55 Astellas Pharma Inc.: Key Developments

Table 56 Faromed Lifesciences LLP: Overview

Table 57 Faromed Lifesciences LLP: Product Portfolio

Table 58 Faromed Lifesciences LLP: Key Developments

Table 59 Matrix Pharma: Overview

Table 60 Matrix Pharma: Product Portfolio

Table 61 Matrix Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 2 Global Helicobacter Pylori Infection Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure 3 Global Helicobacter Pylori Infection Therapeutics Market Share, By Therapeutics, 2022 & 2031 (%)

Figure 4 Global Helicobacter Pylori Infection Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Helicobacter Pylori Infection Therapeutics Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Helicobacter Pylori Infection Therapeutics Market Y-o-Y Growth, By Disease Type, 2022-2031 (%)

Figure 7 Type I H. Pylori Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 8 Type II H. Pylori Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 9 Global Helicobacter Pylori Infection Therapeutics Market Y-o-Y Growth, By Therapeutics, 2022-2031 (%)

Figure 10 Antibiotics Therapeutics in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 11 Proton Pump Inhibitors (PPIs) Therapeutics in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 12 Histamine (H-2) Blockers Therapeutics in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 13 Stomach-Lining Protectors Therapeutics in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 14 Bismuth Subsalicylate Therapeutics in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 15 Others Therapeutics in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 16 Global Helicobacter Pylori Infection Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 20 Global Helicobacter Pylori Infection Therapeutics Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 21 North America Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 22 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 23 Europe Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 24 South America Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 25 Middle East and Africa Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 26 North America Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 27 North America Helicobacter Pylori Infection Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure 28 North America Helicobacter Pylori Infection Therapeutics Market Share, By Therapeutics, 2022 & 2031 (%)

Figure 29 North America Helicobacter Pylori Infection Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 30 North America Helicobacter Pylori Infection Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 31 South America Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 32 South America Helicobacter Pylori Infection Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure 33 South America Helicobacter Pylori Infection Therapeutics Market Share, By Therapeutics, 2022 & 2031 (%)

Figure 34 South America Helicobacter Pylori Infection Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 35 South America Helicobacter Pylori Infection Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 36 Europe Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 37 Europe Helicobacter Pylori Infection Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure 38 Europe Helicobacter Pylori Infection Therapeutics Market Share, By Therapeutics, 2022 & 2031 (%)

Figure 39 Europe Helicobacter Pylori Infection Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 40 Europe Helicobacter Pylori Infection Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 41 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure 43 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Share, By Therapeutics, 2022 & 2031 (%)

Figure 44 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 45 Asia-Pacific Helicobacter Pylori Infection Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 46 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 47 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure 48 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Share, By Therapeutics, 2022 & 2031 (%)

Figure 49 Middle East & Africa Helicobacter Pylori Infection Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 50 Phathom Pharmaceuticals: Financials

Figure 51 Akums Drugs & Pharmaceuticals Ltd.: Financials

Figure 52 RedHill Biopharma Ltd.: Financials

Figure 53 Cumberland Pharmaceuticals Inc.: Financials

Figure 54 Eisai Co., Ltd.: Financials

Figure 55 Takeda Pharmaceutical Company Limited: Financials

Figure 56 Pernix Therapeutics LLC: Financials

Figure 57 Astellas Pharma Inc.: Financials

Figure 58 Faromed Lifesciences LLP: Financials

Figure 59 Matrix Pharma: Financials

세계 헬리코박터 파일로리 감염 치료제 시장 – 2023-2030

Global Helicobacter Pylori Infection Therapeutics Market - 2023-2030